Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE™ Bioresorbable Scaffold
MOUNTAIN VIEW, CA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, presented positive six-month angiographic results from its first-in-human study including patients undergoing percutaneous coronary intervention (PCI) with single coronary lesions. The FORTITUDE™ non-drug eluting bioresorbable scaffold was successfully delivered in 12 patients within the target lesion. Post-deployment angiographic and IVUS analysis indicated that the FORTITUDE scaffold maintained its mechanical integrity, showing no indication of vessel recoil or other structural failures. At the time of the presentation, 10 patients had completed six-month angiographic follow up and six patients had available independent angiographic analysis indicating 0% binary restenosis. The data was presented at the "Next generation DES and bioabsorbable scaffolds" session at the Transcatheter Cardiovascular Therapeutics (TCT) meeting on October 27, 2013 in San Francisco, CA.
Help employers find you! Check out all the jobs and post your resume.